Inovio announces strategic reorganization, continues efforts to focus on promising dna medicine candidates

Cost-saving measures include 11% headcount reduction annual savings expected to be approximately $4.3 million data readouts expected in first quarter of 2023 for key programs including ino-3107 for rrp and vgx-3100 for cervical hsil plymouth meeting, pa. , jan. 31, 2023 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of dna medicines to patients.
INO Ratings Summary
INO Quant Ranking